Therefore, we have consecutively investigated 21 patients with 1) clinical symptoms compatible with either CAPS, FMF or TRAPS and 2) genetically proven low penetrance variants or pathogenic mutations in the respective genes, including NLRP3, MEFV or TNFRSF1A. This evidence concerns the gene MEFV and familial Mediterranean fever.